Last reviewed · How we verify
Shenfu Injection
At a glance
| Generic name | Shenfu Injection |
|---|---|
| Also known as | Shenfu Zhusheye, 5% GS solution |
| Sponsor | Beijing Anzhen Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Shenfu Injection Modulates Carotid Elasticity in Septic Shock (PHASE4)
- The Preventive Effect of Shenfu Injection on Myocardial Dysfunction in Sepsis (PHASE4)
- Clinical Research on Shenfu Injection in Septic Patients (NA)
- Shenfu Injection for Postoperative Delirium (SFI for POD) (NA)
- Randomized Evaluation of Shenfu Injection to Reduce Myocardial Injury (PHASE4)
- Shenfu Injection Improves Arterial Vascular Reactivity (PHASE2, PHASE3)
- ShenFu Injection for Myocardial Protection in Patients With Acute ST Segment Elevation Myocardial Infarction (PHASE4)
- A Study to Evaluate the Efficacy and Safety of Shenfu Zhusheye in Patients With Acute Heart Failure (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Shenfu Injection CI brief — competitive landscape report
- Shenfu Injection updates RSS · CI watch RSS
- Beijing Anzhen Hospital portfolio CI